Micro-x Ltd. · ASX:MX1
Micro-x — FY2025 Earnings Presentation
24 slides from Micro-x's earnings presentation, Aug 28, 2025
Slide 1: Financial Results & Operational Update
FINANCIAL RESULTS & OPERATIONAL UPDATE Financ ial Year ended 30 June 2025 Kingsley Hall C h i e f E x e c u t iv e O f f i c e r 28 August 2025 Micro-X Investor Presentation I 1
Slide 2: Important Notice
IMPORTANT NOTICE S C O P E & L I M I T A T I O N S This Presentation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company’s assets and liabilities, financial position and performance, pr
Slide 3: Creating Revolutionary X-ray Imaging to Better Lives
CREATING REVOLUTIONARY X-RAY IMAGING TO BETTER LIVES Curious I Collaborative I Determine d Micro-X Investor Presentation I 3
Slide 4: Overview
OVERVIEW Growing commercial momentum with Nano Electronic X-ray technology 1 Delivered FY25 Total Revenue of $13.1M - growing sales pipeline into FY26 2 Development work supported by partners – funding grew by $36.6M in FY251 3 Refocused Rover Plus sales strategy building momentum - Major US healthc
Slide 5: World First Imaging Technology
WORLD FIRST IMAGING TECHNOLOGY Proprietary NEX Technology redefines portability and precision for X-ray innovation Micro-X imaging solution – X-ray Tubes – Generators – HV Connectors – Software Micro-X Investor Presentation I 5
Slide 6: Medical Imaging Portfolio
MEDICAL IMAGING PORTFOLIO Pioneering smaller, smarter X-ray and CT through patented technology platform ROVER PLUS HEAD CT FULL BODY CT - MOBILE DIGITAL RADIOGRAPHY - MOBILE STROKE DIAGNOSIS - PORTABLE IMAGING SOLUTION Ultra-mobile x-ray systems delivering high quality Light, portable CT imaging to
Slide 7: Validation & Partners
VALIDATION & PARTNERS Non dilutive funding to de-risk development and unlock value $29m funding $25m funding $8m funding Development Checkpoints & Baggage Full Body CT Head CT Partners Scanner – U.S. Airports – Stroke Diagnosis – Portable & Lightweight >$80m partnership funding Collaboration Partner
Slide 8: Results & Highlights
RESULTS & HIGHLIGHTS F i n a n c i a l Y e a r e n d e d 3 0 J u n e 2 0 2 5
Slide 9: Key Financials – FY25
KEY FINANCIALS – FY25 Growing commercial momentum driving tangible results $13.1M $10.5M ($15.2M) 14% 18.7% 5.8% Total Revenue1 Project Revenue Operating EBITDA2 [FY24: $15.2M] [FY24 $8.8M] [FY24 -$14.3M] Product sales declined with no Govt. orders. Revenue derived from milestones achieved Managed c
Slide 10: Operational Achievements
OPERATIONAL ACHIEVEMENTS New commercialisation strategy delivering results Major U.S. Supply Agreement $25M to fund Full Body CT $6.0M DHS Contract Ext. Supply Agreement with U.S. healthcare group – ARPA-H funding to develop and deliver a Full Contract with U.S. Dept. of Homeland Security over 700 h
Slide 11: Revenue Highlights – FY25
REVENUE HIGHLIGHTS – FY25 Revenue driven by strong partnership activity – offsetting lumpy product income $2.6M Product Revenue $10.5M Project Revenue $13.1M Total Revenue → DHS - $4.6M for Checkpoint + Baggage Scanner → Transitioning the sales strategy towards high-quality, high- → Signed major US
Slide 12: Partnership Funding – FY25
PARTNERSHIP FUNDING – FY25 Reducing the cost base through partners funding product development $36.6M $12.0M $1.5M 50% 46% Partnership Partnership Unfunded Funding Secured Funding Receipts Development Costs → 46% reduction in unfunded → Up to $25M ARPA-H funding → 50% increase in partnership develop
Slide 13: Balance Sheet
BALANCE SHEET All development workstreams fully funded by partnerships Balance Sheet $000 Cash & Cash Equivalents 3,242 $17.9M Trade and Other Receivables 8,321 Inventories 4,274 Contracted payments for FY2026 onwards1 Other Current Assets 1,243 → Prioritising partnership funding to develop Total Cu
Slide 14: Building Commercial Traction
BUILDING COMMERCIAL TRACTION K e y b u i l d i n g b l o c k s a r e i n p l a c e
Slide 15: Strategies & Priorities
STRATEGIES & PRIORITIES Three key near-term objectives focus to drive execution with a focus on tangible outcomes 01 02 03 Deliver large Commence Monetise Rover Plus Sales Head CT imaging trials Security Division – Major healthcare group supply agreement - Pathway to regulatory application in 2026 –
Slide 16: Strong Commercial Momentum
STRONG COMMERCIAL MOMENTUM Commercial activity increasing for FY26 Executing on Rover Plus sales opportunities 1 → Supply Contract in place with Major US Healthcare Group operates over 700 healthcare facilities → Negotiations with major US Group Purchasing Organisation → Ongoing major tenders in pro
Slide 17: Commercial Timeline
COMMERCIAL TIMELINE Commercialising a portfolio of products Products Funding / Status 2025 2026 2027 Approved / Revenue Execute larger Cashflow positive Further growth 400+ units sold to date sales opportunities operations 3D Images - Prototype Human imaging Regulatory Approval & Launch $8m ASA fund
Slide 18: Corporate & Financials
CORPORATE Retail and HNW Institutional /Strategic 42.5% & FINANCIALS 55.2% Board & Management 2.3% FINANCIALS & SHAREHOLDERS SHARE CAPITAL (26 August 2025) $17.9M Contracted Payments FY26 onwards ~$3.2M (30 June 2025) Cash Share price $0.079 per share [$1.9M received in July 25] Revenue $13.1M (FY25
Slide 19: Experienced Leadership
EXPERIENCED LEADERSHIP Commercially focused to accelerate growth Kingsley Hall – CEO Brian Gonzales, PhD – CEO Americas Patrick O'Brien , Non-Exec Chair Jim McDowell, Non-Exec 25+ years exp in senior operational and Recognised industry leader in x-ray physics, CNT Former Senior Exec. Macquarie Forme
Slide 20: Ethical & Sustainable Corporate Growth
ETHICAL & SUSTAINABLE CORPORATE GROWTH Environmental, Social and Governance credentials ENVIRONMENT PEOPLE GOVERNANCE 24% 25% ZERO Female employees Female board US FDA, EU MDR, Environmental incidents 16 nationalities Veterans ARTG Employment represented Commitment Development of 2026 Diversity & Au
Slide 21: Wrap Up
WRAP UP A clear path forward 1 Commercial & customer focus is delivering results 2 Rover Plus sales momentum – building towards breakeven 3 Stroke imaging about to commence trials 4 Near term opportunity to monetise security business 5 Validated by strong partners – funding & access Micro-X Investor
Slide 22: Appendices
APPENDICES F Y 2 5 F i n a n c i a l S t a t e m e n t s Micro-X Investor Presentation I 22
Slide 23: Profit & Loss – FY25
PROFIT & LOSS – FY25 Consolidated 30-Jun-24 30-Jun-25 Change $'000 $'000 $'000 % Key Points Revenues Product Revenue 6,410 2,590 (3,820) -60% → Product Revenue decreased in FY25 with the focus on Costs of Goods sold (5,403) (2,426) 2,977 -55% securing larger opportunities with longer sales cycles Pr
Slide 24: Balance Sheet – FY25
BALANCE SHEET – FY25 Consolidated 30-Jun-24 30-Jun-25 Change $'000 $'000 $'000 % Assets Current assets Cash and cash equivalents 3,228 3,242 14 0% Trade and other receivables 7,212 8,321 1,109 15% Key points Contract assets Inventories 2,941 5,379 839 4,274 (2,102) (1,105) -71% -21% Other Assets 1,1